Login to Your Account



Beigene's PD-1 MAb goes to Australia for first-in-human trials

By Shannon Ellis
Staff Writer

Monday, June 8, 2015
SHANGHAI – The Beijing-based oncology company Beigene Co. Ltd. continuing its string of upbeat news, announcing the first human dosing of its programmed death-1 (PD-1) antibody, BGB-A317, in Australia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription